TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President & Chief Executive Officer James Young - Chief Financial Officer Richard Marshall - Medical Director Conference Call Participants Carl Burns - Northland Capital Markets Justin Walsh - JonesTrading Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity ...

Financial Data and Key Metrics Changes - Product sales in North America increased by 42% year-over-year, contributing to an overall product sales increase of 8% to $3.19 million for the twelve months ended December 31, 2024, compared to $2.96 million for the same period in 2023 [10][17] - Total revenue rose slightly to $3.29 million for the twelve months ended December 31, 2024, from $3.23 million in 2023, driven by increased product sales [17] - Gross profit increased by 12% to $1.45 million, with gross margin improving to 44% from 40% year-over-year [18] - Net loss increased by 5% to $15.32 million or $0.30 per share during the twelve months ended December 31, 2024, compared to a net loss of $14.65 million or $0.32 per share for the same period last year [20] Business Line Data and Key Metrics Changes - The growth in sales was primarily driven by the adoption of ProSense cryoablation across various indications, particularly in breast cancer, with 33 investigator-initiated studies presented in 2024 [10][12] - Non-GAAP gross profit from product sales increased by 32% to $1.35 million, with non-GAAP gross margin rising to 42% from 35% year-over-year [18] Market Data and Key Metrics Changes - The company noted sales momentum in Europe, Japan, and other parts of Asia, indicating a growing international presence [10] - The company is awaiting FDA approval for ProSense, which is expected to enhance sales momentum in the U.S. market [12][14] Company Strategy and Development Direction - The company is focused on innovation and patenting new technologies, including the next-generation cryoablation system, XSEN, which is already FDA cleared for the same indication as ProSense [16] - A soft launch of XSEN is planned for early next year, with the intention of eventually replacing ProSense as the flagship product [41][42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the FDA's decision on ProSense, citing a favorable recommendation from the FDA Medical Device Advisory Committee [14] - The company is actively engaged with the FDA and believes that the approval process is progressing, despite delays [31][32] Other Important Information - The company raised $2.6 million in net proceeds from the sale of ordinary shares between January 13, 2025, and March 24, 2025 [20] - The company continues to manage costs diligently while prioritizing investments in marketing, sales, and research and development [21] Q&A Session Summary Question: Update on ProSense cryoablation procedures and US commercial efforts - Management confirmed ongoing activities at major hospitals like Emory, UCLA, and Mayo Clinic, with a focused sales team in the U.S. awaiting FDA approval [24][27] Question: Timing of FDA approval and sales hiring - Management indicated that delays are due to the evolving situation at the FDA, but they remain engaged and hopeful for a favorable decision [31][34] Question: Update on regulatory filing in Japan - Management stated that Terumo Corporation plans to submit a regulatory filing in Japan in the second semester of 2025 [36] Question: Dynamic between XSEN and ProSense - Management clarified that XSEN is intended to replace ProSense in the long run, with a soft launch planned for 2026 [41][45]

Jiayin Group Inc. (NASDAQ:JFIN) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Shawn Zhang ??? Investor Relations Yan Dinggui ??? Chief Executive Officer Fan Chunlin ??? Chief Financial Officer Xu Yifang ??? Chief Risk Officer Conference Call Participants Yong Zhao ??? Haitong Securities Hua Rong ??? Jinyu Asset Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to Jiayin Group Fourth Quarter 2024 Earnings Conference Call. Currently all participa ...

Alvotech (NASDAQ:ALVO) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Robert Wessman - Chairman, Chief Executive Officer Anil Okay - Chief Commercial Officer Joseph McClellan - Chief Scientific Officer Joel Morales - Chief Financial Officer Benedikt Stefannson - Vice President, Investor Relations Conference Call Participants Ashwani Verma - UBS Operator Good day and thank you for standing by. Welcome to the Alvotech Q4 2024 earnings call. At this time, all participants are ...

Bitfarms Ltd. (NASDAQ:BITF) Q4 2024 Earnings Conference Call March 26, 2025 8:00 AM ET Company Participants Tracy Krumme - SVP of Investor Relations & Corporate Communications Ben Gagnon - Chief Executive Officer & Director Jeffrey Lucas - Chief Financial Officer Conference Call Participants Brett Knoblauch - Cantor Fitzgerald Mike Colonnese - H.C. Wainwright & Company Mike Grondahl - Northland Capital Markets Brian Kinstlinger - Alliance Global Partners Nick Giles - B. Riley Bill Papanastasiou - KBW Brian ...

EDAP TMS S.A. (NASDAQ:EDAP) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants John Fraunces - IR, LifeSci Advisors Ryan Rhodes - CEO Ken Mobeck - CFO Conference Call Participants Michael Sarcone - Jefferies Swayampakula Ramakanth - H.C. Wainwright Operator Good day, everyone, and welcome to today's EDAP TMS Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. Later, you will have the opportunity to ask questions du ...

3D Systems Corporation (NYSE:DDD) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Mick McCloskey - VP, IR Jeffrey Graves - President and CEO Jeff Creech - EVP and CFO Conference Call Participants Jim Ricchiuti - Needham & Company Troy Jensen - Cantor Fitzgerald Greg Palm - Craig-Hallum Capital Group Operator Greetings, and welcome to the 3D Systems Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast. At this time all participants are in a listen-only mode ...

Marpai, Inc. (OTCQX:MRAI) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Steve Johnson - Chief Financial Officer Damien Lamendola - Chief Executive Officer and Director John Powers - President Conference Call Participants Ian Cassel - IFCM Operator Good morning, and welcome to the Marpai Fourth Quarter and Full-Year 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation there will be an opportunity to ...

Financial Data and Key Metrics Changes - The company ended 2024 with $251 million in cash and cash equivalents, expected to fund operations into the second half of 2026 [24] - ZYNLONTA net product revenues for Q4 2024 were $16.4 million, slightly down from $16.6 million in Q4 2023, while full-year revenues were $69.3 million compared to $69.1 million in 2023 [25] - The net loss for Q4 2024 was $30.7 million, a significant improvement from a net loss of $85 million in Q4 2023 [26] - For the full year, the net loss was $157.8 million, down from $240.1 million in 2023 [26] - Non-GAAP operating expenses decreased by 15% year-over-year in Q4 2024, contributing to the reduced net loss [25][26] Business Line Data and Key Metrics Changes - ZYNLONTA maintained its position in the third-line-plus DLBCL market, achieving commercial brand profitability [9] - The company reported an overall response rate of 80% and a complete response rate of 50% in the LOTIS-5 trial, indicating strong efficacy [13] - Initial data from LOTIS-7 showed a best overall response rate of 94% and a complete response rate of 72% among relapsed or refractory DLBCL patients [14] Market Data and Key Metrics Changes - The company anticipates a peak revenue opportunity of $600 million to $1 billion in the US for ZYNLONTA, assuming regulatory approval and compendia listing [19][21] - The potential market opportunity for indolent lymphomas is estimated to be between $100 million and $200 million [22] Company Strategy and Development Direction - The company aims to expand the use of ZYNLONTA into earlier lines of DLBCL therapy through ongoing trials [13] - The strategy includes pursuing research collaborations to advance early-stage solid tumor pipelines [29] - The focus remains on hematology, with a disciplined capital allocation strategy to create value [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's path forward, highlighting the importance of upcoming data readouts in 2025 [30] - The competitive landscape is expected to evolve with the introduction of new therapies, but management believes ZYNLONTA will maintain its market position [76] Other Important Information - The company achieved a double-digit reduction in operating expenses for the second consecutive year [12] - Management emphasized the importance of regulatory strategies and compendia listings for future growth [50] Q&A Session Summary Question: Update on LOTIS-7 - The company has not disclosed the specific forum or timing for sharing LOTIS-7 data but is on track to enroll 40 patients in Q2 [42] Question: Impact of ADCETRIS Approval - Management believes the approval of ADCETRIS will have limited impact on ZYNLONTA's market share, as it is likely to replace older regimens rather than significantly affect current usage [44] Question: Regulatory Meetings for LOTIS-7 - Discussions with regulatory authorities are planned for the second half of the year once sufficient data is available [50] Question: Market Opportunity in Indolent Lymphoma - The peak opportunity for indolent lymphomas is estimated to be between $100 million and $200 million [51] Question: LOTIS-5 and LOTIS-7 Strategy - Both LOTIS-5 and LOTIS-7 are seen as complementary approaches to address different patient needs in the DLBCL market [56] Question: Importance of Upcoming Presentations - The upcoming presentations at AACR are expected to provide differentiating data on the company's ADC platforms [60] Question: Competitive Landscape for DLBCL - The introduction of bispecifics has taken about a third of the third-line-plus market, but ZYNLONTA has maintained consistent sales [75] Question: Compendia Listing and Market Penetration - Peak penetration for ZYNLONTA is typically achieved within the first two years post-approval or listing [86]

Inventiva S.A. (NASDAQ:IVA) Q4 2024 Earnings Call March 27, 2025 8:00 AM ET Company Participants Fr??d??ric Cren - CEO Jean Volatier - CFO Pierre Broqua - CSO Conference Call Participants Unidentified Analyst - TD Cowen Unidentified Analyst - Jefferies & Co. Annabel Samimy - Stifel Ed Arce - HC Wainwright Jacob Mekhael - KBC Securities Rami Katkhuda - LifeSci Capital Unidentified Analyst - UBS Operator Good day and thank you for standing by. Welcome to the Inventiva Full Year 2024 Financial Results Webcast ...